| Latest Novadel Pharma News Headlines |
| Date | Time | Source | |
| 2005/03/09 | 21 : 52 | PRNUS | Inyx Announces Expanded Relationship with NovaDel Pharma
Inyx Announces Expanded Relationship with NovaDel Pharma
NEW YORK, March 9 /PRNewswire-FirstCall/ -- Inyx, Inc. (OTC Bulletin Board:
IYXI), a specialty pharmaceutical company with a focus on niche drug delivery
technologies and products, announced today that it has signed a letter of
intent with NovaDel Pharma Inc... More...>> |
| 2005/02/09 | 20 : 43 | PRNUS | New Clinical Trial to Study First Oral Spray to Reduce Chemotherapy-Induced Nausea and Vomiting
New Clinical Trial to Study First Oral Spray to Reduce
Chemotherapy-Induced Nausea and Vomiting
* Oral Spray Expected to Be Faster and More Convenient Than Zofran(R) for
Active Chemotherapy Patients
SOUTH SAN FRANCISCO, Calif., Feb. 9 /PRNewswire-FirstCall/ -- Hana
Biosciences, Inc. (OTC:HNAB) (BULLETIN BOARD: HNAB... More...>> |
| 2004/12/22 | 20 : 33 | PRNUS | NovaDel Names Michael Spicer Chief Financial Officer
NovaDel Names Michael Spicer Chief Financial Officer
FLEMINGTON, N.J., Dec. 22 /PRNewswire-FirstCall/ -- NovaDel Pharma, Inc.
(AMEX:NVD), today announced that it has appointed Michael E. Spicer to the
position of chief financial officer. Mr. Spicer brings NovaDel over 20 years'
experience in finance, accounting and... More...>> |
| 2004/12/15 | 21 : 29 | PRNUS | NovaDel Reports First Quarter Fiscal Year 2005 Results
NovaDel Reports First Quarter Fiscal Year 2005 Results
FLEMINGTON, N.J., Dec. 15 /PRNewswire-FirstCall/ -- NovaDel Pharma, Inc.
(AMEX:NVD) reported results for the three months ended October 31, 2004, the
first quarter of its 2005 fiscal year.
The net loss for the period was $2.3 million, or seven cents per share,
compared... More...>> |
| 2004/12/08 | 21 : 29 | PRNUS | NovaDel Names Henry Kwan, PhD Head Of Pharmaceutical Sciences
NovaDel Names Henry Kwan, PhD Head Of Pharmaceutical Sciences
FLEMINGTON, N.J., Dec. 8 /PRNewswire-FirstCall/ -- NovaDel Pharma, Inc.
(AMEX:NVD) announced that Henry Kwan, PhD joined the company as Head of
Pharmaceutical Sciences.
Most recently Dr. Kwan was Vice President, R&D and Regulatory Affairs for
Eurand, Inc... More...>> |
| 2004/12/07 | 21 : 29 | PRNUS | NovaDel Pharma Initiates Human Study of Lingual Spray Version of World's Leading Sleep Agent
NovaDel Pharma Initiates Human Study of Lingual Spray Version of
World's Leading Sleep Agent
Zolpidem is Company's Fourth Product Candidate To Enter Human Testing This Year
FLEMINGTON, N.J., Dec. 7 /PRNewswire-FirstCall/ -- NovaDel Pharma Inc.
(AMEX:NVD) said it initiated a pilot pharmacokinetic feasibility study in
humans... More...>> |
| 2004/11/23 | 23 : 32 | PRNUS | Inyx Selected by NovaDel Pharma to Produce Nitroglycerin Lingual Spray
Inyx Selected by NovaDel Pharma to Produce Nitroglycerin Lingual
Spray
NEW YORK, Nov. 23 /PRNewswire-FirstCall/ -- Inyx, Inc. (OTC Bulletin Board:
IYXI), a specialty pharmaceutical company with a focus on niche drug delivery
technologies and products, announced today that it has been selected by NovaDel
Pharma Inc... More...>> |
| 2004/11/16 | 21 : 00 | PRNUS | NovaDel Reports Results For Fiscal 2004
NovaDel Reports Results For Fiscal 2004
10K Filing includes non-cash restatement of FY 2003
FLEMINGTON, N.J., Nov. 16 /PRNewswire-FirstCall/ -- NovaDel Pharma Inc.
(AMEX:NVD) reported results for the fiscal year ended July 31, 2004 and
restated results for fiscal 2003.
Net losses for the period were $6,341,000... More...>> |
| 2004/10/27 | 20 : 29 | PRNUS | NovaDel Licenses Lingual Spray Version of Leading Anti-emetic, Ondansetron, to Hana Biosciences, Inc.
NovaDel Licenses Lingual Spray Version of Leading Anti-emetic,
Ondansetron, to Hana Biosciences, Inc.
FLEMINGTON, N.J., Oct. 27 /PRNewswire-FirstCall/ -- NovaDel Pharma Inc.
(AMEX:NVD) said it entered into a licensing agreement with Hana Biosciences,
Inc. of South San Francisco (OTC:HNAB) (BULLETIN BOARD: HNAB) to... More...>> |
| 2004/10/27 | 20 : 00 | PRNUS | Hana Biosciences Licenses Rights to Proprietary Lingual Spray from NovaDel Pharma for Chemotherapy-Induced Nausea and Vomiting
Hana Biosciences Licenses Rights to Proprietary Lingual Spray
from NovaDel Pharma for Chemotherapy-Induced Nausea and Vomiting
SOUTH SAN FRANCISCO, Calif., Oct. 27 /PRNewswire-FirstCall/ -- Hana
Biosciences, Inc. (OTCBB: HNAB), a biopharmaceutical company headquartered in
South San Francisco, California announced today... More...>> |
| 2004/10/23 | 00 : 19 | PRNUS | NovaDel to Present at Rodman & Renshaw TechVest Conference in New York October 27
NovaDel to Present at Rodman & Renshaw TechVest Conference in New
York October 27
FLEMINGTON, N.J., Oct. 22 /PRNewswire-FirstCall/ -- NovaDel Pharma, Inc.
(AMEX:NVD) will provide an update on the company's product portfolio and
clinical development plans for it oral mucosa delivery technology at the Rodman
& Renshaw... More...>> |
| 2004/10/14 | 20 : 29 | PRNUS | NovaDel Successfully Delivers Sumatriptan (Imitrex(R)) Via Lingual Spray
NovaDel Successfully Delivers Sumatriptan (Imitrex(R)) Via
Lingual Spray
Data Indicates Absorption Through Oral Mucosa Holds Promise of Faster-Acting
Migraine Remedy With NovaDel Technology
FLEMINGTON, N.J., Oct. 14 /PRNewswire-FirstCall/ -- NovaDel Pharma Inc.
(AMEX:NVD) reported preliminary findings of an important... More...>> |
| 2004/10/13 | 01 : 43 | PRNUS | S.W. Bach Initiates Coverage on Novadel
S.W. Bach Initiates Coverage on Novadel
PORT WASHINGTON, N.Y., Oct. 12 /PRNewswire/ -- S.W. Bach & Company, Inc. said
it initiated coverage on NovaDel Pharma Inc. (AMEX:NVD) with a speculative buy
recommendation and a 12-month price target of $4.50. The price target assumes
significant milestones are met in NovaDel's... More...>> |
| 2004/09/29 | 20 : 29 | PRNUS | NovaDel NDA for Nitroglycerin Lingual Spray is Accepted for Review by FDA
NovaDel NDA for Nitroglycerin Lingual Spray is Accepted for
Review by FDA
Par Pharmaceutical Has Exclusive Rights To U.S. And Canada
FLEMINGTON, N.J., Sept. 29 /PRNewswire-FirstCall/ -- NovaDel Pharma Inc.
(AMEX:NVD) today announced that the NDA for its aerosol nitroglycerin lingual
spray has been accepted for review... More...>> |
| 2004/09/23 | 20 : 29 | PRNUS | NovaDel Initiates Human Study of Lingual Spray Version of Pfizer's Xanax(R), the Leading Anti-Anxiety Drug
NovaDel Initiates Human Study of Lingual Spray Version of
Pfizer's Xanax(R), the Leading Anti-Anxiety Drug
Announcement Covers Third of Five Products Scheduled for Testing in Humans This
Year
FLEMMINGTON, N.J., Sept. 23 /PRNewswire-FirstCall/ -- NovaDel Pharma Inc.
(AMEX:NVD) said it has commenced a pilot pharmacokinetic... More...>> |
| 2004/09/15 | 18 : 58 | PRNUS | NovaDel Pharma to Present at Equities Magazine Discovery Day XI Conference Today
NovaDel Pharma to Present at Equities Magazine Discovery Day XI
Conference Today
FLEMINGTON, N.J., Sept. 15 /PRNewswire-FirstCall/ -- NovaDel Pharma, Inc.
(AMEX:NVD), a leading formulator of lingual spray drugs for systemic delivery
through the oral mucosa, said Gary A. Shangold, MD, president and chief
executive officer... More...>> |
| 2004/09/14 | 21 : 03 | PRNUS | Velcera Pharmaceuticals Gains Exclusive License for Proprietary Lingual Spray Technology from NovaDel
Velcera Pharmaceuticals Gains Exclusive License for Proprietary
Lingual Spray Technology from NovaDel
New Veterinary Company Will Commercialize Novel Drug Delivery Technology for
Pets, Other Animals
LANGHORNE, Pa., Sept. 14 /PRNewswire/ -- Velcera Pharmaceuticals, Inc.
announced today it has entered into an agreement... More...>> |
| 2004/09/14 | 20 : 29 | PRNUS | NovaDel Grants Exclusive License for Animal Drugs Using Proprietary Lingual Spray Technology
NovaDel Grants Exclusive License for Animal Drugs Using
Proprietary Lingual Spray Technology
Former Senior Animal Health Executives Will Commercialize NovaDel's Drug
Delivery Technology for Pets, Other Animals
FLEMINGTON, N.J., Sept. 14 /PRNewswire-FirstCall/ -- NovaDel Pharma, Inc.
(AMEX:NVD) granted an exclusive worldwide... More...>> |
| 2004/09/08 | 20 : 30 | PRNUS | Par Pharmaceutical Licenses Nitroglycerin Lingual Spray From NovaDel Pharma Inc.
Par Pharmaceutical Licenses Nitroglycerin Lingual Spray From
NovaDel Pharma Inc.
Agreement Provides Par Access to Potential New Product
SPRING VALLEY, N.Y., Sept. 8 /PRNewswire-FirstCall/ -- Par Pharmaceutical
Companies, Inc. (NYSE:PRX) today announced that it has entered into a licensing
agreement with developer NovaDel... More...>> |
| 2004/09/08 | 20 : 29 | PRNUS | NovaDel Licenses Nitroglycerin Lingual Spray to Par Pharmaceutical
NovaDel Licenses Nitroglycerin Lingual Spray to Par
Pharmaceutical
FLEMINGTON, N.J., Sept. 8 /PRNewswire-FirstCall/ -- NovaDel Pharma Inc.
(AMEX:NVD) announced that is has entered into a licensing agreement with Par
Pharmaceutical (NYSE:PRX) to market its nitroglycerin lingual spray.
In June, NovaDel filed a New Drug... More...>> |